Sernova (TSE:SVA) Shares Up 27.8% – Should You Buy?

Sernova Corp. (TSE:SVA) shares shot up 27.8% during mid-day trading on Wednesday. The stock traded as high as C$0.12 and last traded at C$0.12. Approximately 560,229 shares were traded during mid-day trading, an increase of 276% from the average daily volume of 149,033 shares. The stock had previously closed at C$0.09.

Sernova Stock Up 27.8%

The company has a debt-to-equity ratio of -21.98, a current ratio of 0.03 and a quick ratio of 18.11. The stock has a market cap of C$43.43 million, a price-to-earnings ratio of -1.64 and a beta of -0.43. The firm’s 50-day moving average is C$0.11 and its 200 day moving average is C$0.14.

Sernova (TSE:SVA) last announced its quarterly earnings data on Thursday, September 10th. The company reported C($0.01) earnings per share (EPS) for the quarter. Sell-side analysts anticipate that Sernova Corp. will post -0.08 earnings per share for the current fiscal year.

About Sernova

Sernova Biotherapeutics is a clinical-stage company developing regenerative medicine therapeutics combining its Cell Pouch with human donor cells or stem-cell derived islet-like clusters in collaboration with Evotec to create bio-hybrid organs to treat T1D. A bio-hybrid organ is comprised of non-biomaterials, such as the Cell Pouch, integrated with living tissues to restore or enhance the function of a compromised organ. This innovative approach aims to deliver a potentially revolutionary treatment for patients with chronic diseases, initially focusing on T1D and thyroid disorders.